PALVELLA THERAPEUTICS, INC. (PVLA): Nasdaq/NYSE listing notice — Pieris receives Nasdaq bid-price deficiency notice; 180-day cure period

PALVELLA THERAPEUTICS, INC.

Closing bid price below $1.00 for 30 consecutive business days triggers deficiency under Nasdaq Listing Rule 5550(a)(2).
Company has until November 13, 2023 to regain compliance; needs $1.00+ close for 10 consecutive days.
If not cured by initial date, may be eligible for additional 180-day period if other listing standards are met.
Options being considered include a reverse stock split; no immediate effect on trading under symbol PIRS.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PALVELLA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 15, 2023, Pieris Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). This Not

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-149296

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.